Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ: RLMD )

0.2805 +0.0105 (+3.89%)
Streaming Delayed Price Updated: 9:45 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,957
Open 0.2800
Bid (Size) 0.2805 (49)
Ask (Size) 0.2839 (3)
Prev. Close 0.2700
Today's Range 0.2800 - 0.2843
52wk Range 0.2404 - 5.840
Shares Outstanding 17,472,986
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals. 
Via Benzinga

Performance

YTD
-37.68%
-37.68%
1 Month
-1.85%
-1.85%
3 Month
-24.19%
-24.19%
6 Month
-91.42%
-91.42%
1 Year
-95.03%
-95.03%

More News

Read More
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
Via Benzinga
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
A Look Ahead: Relmada Therapeutics's Earnings Forecast
Via Benzinga
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Recap: Relmada Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For Relmada Therapeutics
Via Benzinga
Earnings Outlook For Relmada Therapeutics
Via Benzinga
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 19, 2024
Via Benzinga
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
Via InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.